Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of a new oral elacridar formulation in healthy volunteers
NL-OMON38922Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of elacridar, sponsored by Netherlands Cancer Institute. Primary endpoint: Pharmacokinetic properties of the new elacridar formulation. Started Oct 2013; status: active, not recruiting.
02
Drugs
elacridar
Beyond the preview
Go deeper on NL-OMON38922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38922.